Comparative Pharmacology
Head-to-head clinical analysis: BAQSIMI versus GVOKE VIALDX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAQSIMI versus GVOKE VIALDX.
BAQSIMI vs GVOKE VIALDX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAQSIMI (glucagon) nasal powder is a hormone that increases blood glucose concentration by stimulating hepatic glycogenolysis and gluconeogenesis. It also relaxes smooth muscle of the gastrointestinal tract.
Glucagon receptor agonist; increases intracellular cAMP in hepatocytes, promoting glycogenolysis and gluconeogenesis, thereby elevating blood glucose levels.
3 mg intranasally as a single dose for severe hypoglycemia.
1 mg subcutaneously, intramuscularly, or intravenously; may repeat every 15 minutes if necessary.
None Documented
None Documented
Glucagon has a short plasma half-life of approximately 8–18 minutes after IV administration. For nasal glucagon (BAQSIMI), systemic half-life is similar; clinical effect is brief, and rapid clearance limits duration.
Terminal half-life: 5 minutes (intravenous); clinically, brief half-life allows rapid glucagon effect, but requires continuous infusion for sustained effect.
Primarily renal: metabolites and unchanged drug are excreted in urine. No significant biliary/fecal excretion data reported; glucagon is degraded in plasma, liver, and kidneys.
Renal: negligible; hepatic metabolism to inactive metabolites, with biliary/fecal elimination of metabolites.
Category C
Category C
Glucagon (Antihypoglycemic)
Glucagon (Antihypoglycemic)